Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
Mid-stage data for Tocagen and Restorbio are approaching.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.